ガイドライン

(旧版)急性膵炎診療ガイドライン2010

書誌情報
第IX章  ERCP後膵炎
―消化器内視鏡関連手技後の膵炎―

 

引用文献

1)   Cotton PB, Lehman G, Vennes J, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 1991; 37: 383-393. (診断レベル5)
2)   Loperfido S, Angelini G, Benedetti G, et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc 1998; 48: 1-10. (治療レベル2b)
3)   Lenriot JP, Le Neel JC. Cholangio-pancreatographie retrograde et sphincterotomie endoscopique pour lithiase biliaire: evaluation prospective en milieu chirurgical(in French). Gastroenterol Clin Biol 1993; 17: 244-250. (治療レベル2b)
4)   Reiertsen O, Skjoto J, Jacobsen CD, et al. Complications of fiberoptic gastrointestinal endoscopy -five years' experience in a central hospital. Endoscopy 1987; 19: 1-6. (治療レベル2b)
5)   Sherman S, Hawes RH, Rathgaber SW, et al. Post-ERCP pancreatitis: randomized, prospective study comparing a low-and high-osmolality contrast agent. Gastrointest Endosc 1994; 40: 422-427. (病因レベル1b)
6)   Johnson GK, Geenen JE, Bedford RA, et al. A comparison of nonionic versus ionic contrast media: results of retrospective,multicenter study. Midwest Pancreaticobiliary Study Group. Gastrointest Endosc 1995; 42: 312-316. (病因レベル1b)
7)   Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996; 335: 909-918. (病因レベル2b)
8)   Escourrou J, Cordova JA, Lazorthes F, et al. Early and late complications after endoscopic sphincterotomy for biliary lithiasis with and without the gall bladder `in situ'. Gut 1984; 25: 598-602. (病因レベル4)
9)   Weinberg BM, Shindy W, Lo S. Endoscopic balloon sphincter dilation(sphincteroplasty) versus sphincterotomy for common bile duct stones. Cochrane Database Syst Rev 2006; Oct 18; (4): CD004890. (病因レベル1a)
10)   跡見裕, 税所宏光, 早川哲夫, 他. 内視鏡的乳頭処置に関する研究. 難治性膵疾患に関する調査研究, 平成12年度厚生労働省研究2001; 47-53. (病因レベル4)
11)   Tsujino T, Isayama H, Komatsu Y, et al. Risk factors for pancreatitis in patients with common bile duct stones managed by endoscopic papillary balloon dilation. Am J Gastroenterol 2005; 100(1): 38-42. (病因レベル4)
12)   Masci E, Mariani A, Curioni S, et al. Risk factors for pancreatitis following endoscopic retrograde cholangiopancreatography: a meta-analysis. Endoscopy 2003; 35(10): 830-834. (病因レベル2a)
13)   Sherman S, Ruffolo TA, Hawes RH, et al. Complications of endoscopic sphincterotomy. A prospective series with emphasis on the increased risk associated with sphincter of Oddi dysfunction and nondilated bile ducts. Gastroenterology 1991; 101(4): 1068-1075. (病因レベル2b)
14)   Chen YK, Foliente RL, Santoro MJ, et al. Endoscopic sphincterotomy-induced pancreatitis: increased risk associated with nondilated bile ducts and sphincter of Oddi dysfunction. Am J Gastroenterol 1994; 89(3): 327-333. (病因レベル2b)
15)   Dickinson RJ, Davies S. Post-ERCP pancreatitis and hyperamylasemia: the role of operative and patient factors. Eur J Gastroenterol Hepatol 1998; 10(5): 423-428. (病因レベル2b)
16)   Deans GT, Sedman P, Martin DF, et al. Are complications of endoscopic sphincterotomy age related? Gut 1997; 41(4): 545-548. (病因レベル2b)
17)   De Palma GD, Catanzano C. Use of corticosteriods in the prevention of post-ERCP pancreatitis: results of a controlled prospective study. Am J Gastroenterol 1999; 94(4): 982-985. (病因レベル1b)
18)   Poon RT, Yeung C, Lo CM, et al. Prophylactic effect of somatostatin on post-ERCP pancreatitis: a randomized controlled trial. Gastrointest Endosc 1999; 49(5): 593-598. (病因レベル1b)
19)   Roszler MH, Campbell WL. Post-ERCP pancreatitis: association with urographic visualization during ERCP. Radiology 1985; 157: 595-598. (病因レベル4)
20)   Johnson GK, Geenen JE, Johanson JF, et al. Evaluation of post-ERCP pancreatitis: potential causes noted during controlled study of differing contrast media. Midwest Pancreaticobiliary Study Group. Gastrointest Endosc 1997;46: 217-222. (病因レベル1b)
21)   Cavallini G, Tittobello A, Frulloni L, et al. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy -Italian Group. N Engl J Med 1996; 335(13): 919-923. (病因レベル1b)
22)   Singh P, Das A, Isenberg G, et al. Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled trials. Gastrointest Endosc 2004; 60: 544-550. (治療/予防レベル1a)
23)   Smithline A, Silverman W, Rogers D, et al. Effect of prophylactic main pancreatic duct stenting on the incidence of biliary endoscopic sphincterotomy-induced pancreatitis in high-risk patients. Gastrointest Endosc 1993; 39: 652-657. (治療/予防レベル1b)
24)   Sherman S, Bucksot EL, Esber E, et al. Does leaving a main pancreatic duct stent in place reduce the incidence of precut biliary sphincterotomy-induced pancreatitis? Randomized prospective study. Am J Gastroenterol 1995;90: 241. (治療/予防レベル1b)
25)   Tarnasky PR, Palesch YY, Cunningham JT, et al. Pancreatic stenting prevents pancreatitis after biliary sphincterotomy in patients with sphincter of Oddi dysfunction. Gastroenterology 1998; 115: 1518-1524. (治療/予防レベル1b)
26)   Aizawa T, Ueno N. Stent placement in the pancreatic duct prevents pancreatitis after endoscopic sphincter dilation for removal of bile duct stones. Gastrointest Endosc 2001; 54: 209-213. (治療/予防レベル2b)
27)   Fazel A, Quadri A, Catalano MF, et al: Does a pancreatic duct stent prevent post-ERCP pancreatitis? A prospective randomized study. Gastrointest Endosc 2003; 57: 291-294. (治療/予防レベル1b)
28)   Freeman ML, Guda NM. Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc 2004; 59: 845-864. (治療/予防レベル5)
29)   Sofuni A, Maguchi H, Itoi T, et al. Prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis by an endoscopic pancreatic spontaneous dislodgement stent. Clin Gastroenterol Hepatol 2007; 5: 1339-1346. (治療/予防レベル1b)
30)   Tsuchiya T, Itoi T, Sofuni A. Temporary pancreatic stent to prevent post endoscopic retrograde cholangiopancreatography pancreatitis: a preliminary, single-center, randomized controlled trial. J Hepatobiliary Pancreat Surg 2007; 14: 302-307. (治療/予防レベル1b)
31)   Freeman ML. Pancreatic stents for prevention of post-endoscopic cholangiopancreatography pancreatitis. Clin Gastroenterol Hepatol 2007; 5: 1354-1365. (治療/予防レベル5)
32)   Bailey AA, Bourke MJ, Williams SJ, et al. A prospective randomized trial of cannulation technique in ERCP:effects on technical success and post-ERCP pancreatitis. Endoscopy 2008; 40: 296-301. (治療/予防レベル1b)
33)   Katsinelos P, Paroutoglou G, Kountouras J, et al. A comparative study of standard ERCP catheter and hydrophilic guide wire in the selective cannulation of the common bile duct. Endoscopy 2008; 40: 302-307. (治療/予防レベル1b)
34)   Varadarajulu S, Wilcox CM. Randomized trial comparing needle-knife and pull-sphincterotome techniques for pancreatic sphincterotomy in high-risk patients Gastrointest Endosc 2006; 64: 716-722. (治療/予防レベル1b)
35)   Khatibian M, Sotoudehmanesh R, Ali-Asgari A, et al. Needle-knife fistulotomy versus standard method for cannulation of common bile duct: a randomized controlled trial. Arch Iran Med 2008; 11: 16-20. (治療/予防レベル1b)
36)   Dai HF, Wang XW, Zhao K. Role of nonsteroidal anti-inflammatory drugs in the prevention of post-ERCP pancreatitis: a meta-analysis. Hepatobiliary Pancreat Dis Int 2009; 8: 11-16. (治療/予防レベル1a)
37)   Elmunzer BJ, Waljee AK, Elta GH, et al. A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis. Gut 2008; 57: 1262-1267. (治療/予防レベル1a)
38)   Zheng MH, Xia HH, Chen YP. Rectal administration of NSAIDs in the prevention of post-ERCP pancreatitis: a complementary meta-analysis. Gut 2008; 57: 1632-1633. (治療/予防レベル1a)
39)   Zheng M, Chen Y, Yang X, et al. Gabexate in the prophylaxis of post-ERCP pancreatitis: a meta-analysis of randomized controlled trials. BMC Gastroenterol 2007; 7: 6-13. (治療/予防レベル1a)
40)   Rudin D, Kiss A, Wetz RV, et al. Somatostatin and gabexate for post-endoscopic retrograde cholangiopancreatography pancreatitis prevention: meta-analysis of randomized placebo-controlled trials. J Gastroenterol Hepatol 2007; 22: 977-983. (治療/予防レベル1a)
41)   Andriulli A, Leandro G, Federici T, et al. Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis. Gastrointest Endosc 2007; 65: 624-632. (治療/予防レベル1a)
42)   Manes G, Ardizzone S, Lombardi G, et al. Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study. Gastrointest Endosc 2007; 65:982-987. (治療/予防レベル1b)
43)   Lee KT, Lee DH, Yoo BM. The prophylactic effect of somatostatin on post-therapeutic endoscopic retrograde cholangiopancreatography pancreatitis: a randomized, multicenter controlled trial. Pancreas 2008; 37: 445-448.(治療/予防レベル1b)
44)   Bai Y, Gao J, Zou DW, et al. Prophylactic octreotide administration does not prevent post-endoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis of randomized controlled trials. Pancreas 2008; 37: 241-246. (治療/予防レベル1a)
45)   Zheng M, Chen Y, Bai J, et al. Meta-analysis of prophylactic allopurinol use in post-endoscopic retrograde cholangiopancreatography pancreatitis. Pancreas 2008; 37: 247-253. (治療/予防レベル1a)
46)   Bai Y, Gao J, Zhang W, et al. Meta-analysis: allopurinol in the prevention of postendoscopic retrograde cholangiopancreatography pancreatitis. Aliment Pharmacol Ther 2008; 28: 557-564. (治療/予防レベル1a)
47)   Zheng M, Bai J, Yuan B, et al. Meta-analysis of prophylactic corticosteroid use in post-ERCP pancreatitis. BMC Gastroenterol 2008; 8: 6. (治療/予防レベル1a)
48)   Katsinelos P, Kountouras J, Paroutoglou G, et al. Intravenous N-acetylcysteine does not prevent post-ERCP pancreatitis. Gastrointest Endosc 2005; 62: 105-111. (治療/予防レベル1b)
49)   Milewski J, Rydzewska G, Degowska M, et al. N-acetylcysteine does not prevent post-endoscopic retrograde cholangiopancreatography hyperamylasemia and acute pancreatitis. World J Gastroenterol 2006; 12: 3751-3755.(治療/予防レベル1b)
50)   Tsujino T, Komatsu Y, Isayama H, et al. Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography:a randomized, controlled trial. Clin Gastroenterol Hepatol 2005; 3: 376-383. (治療/予防レベル1b)
51)   Fujishiro H, Adachi K, Imaoka T, et al. Ulinastatin shows preventive effect on post-endoscopic retrograde cholangiopancreatography pancreatitis in a multicenter prospective randomized study. J Gastroenterol Hepatol 2006; 21: 1065-1069. (治療/予防レベル1b)
52)   Ueki T, Otani K, Kawamoto K, et al. Comparison between ulinastatin and gabexate mesylate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized trial. J Gastroenterol 2007; 42: 161-167. (治療/予防レベル1b)
53)   Yoo JW, Ryu JK, Lee SH, et al. Preventive effects of ulinastatin on post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a prospective, randomized, placebo-controlled trial. Pancreas 2008; 37: 366-370. (治療/予防レベル1b)
54)   van Westerloo DJ, Rauws EA, Hommes D, et al. Pre-ERCP infusion of semapimod, a mitogen-activated protein kinases inhibitor, lowers post-ERCP hyperamylasemia but not pancreatitis incidence. Gastrointest Endosc 2008;68: 246-254. (治療/予防レベル1b)
55)   明石隆吉, 伊藤鉄英, 五十嵐良典, 他. ERCP 後膵炎の前向き検討の進捗状況およびERCP 後膵炎の診断基準.病態. 治療に対する考察と今後の対策. 厚生労働省科学研究費補助金分担研究報告書;37-43



 

書誌情報